Risk Score for Asthma Exacerbation (RSE)

Calculate the Risk Score for Asthma Exacerbation (RSE) to predict severe exacerbation risk within 12 months. Uses BMI, ACQ-5 score, post-bronchodilator FEV1, rescue inhaler usage, and GINA treatment step.

RSE Score Calculator

Select the appropriate value for each clinical parameter. The RSE predicts the risk of severe asthma exacerbation within 12 months based on five dominant predictors identified in a cohort of 7,446 patients with poorly controlled asthma.

BMI ≥ 30 kg/m²

Obesity (BMI ≥ 30) is independently associated with increased risk of severe asthma exacerbations, possibly through airway inflammation, altered lung mechanics, and comorbid conditions.

Asthma Control Questionnaire-5 (ACQ-5) Score

The ACQ-5 measures symptom control over the past week (0 = fully controlled, 6 = severely uncontrolled). Higher scores reflect poorer control and greater exacerbation risk.

Post-bronchodilator FEV1 (% predicted)

Forced expiratory volume in 1 second after bronchodilator administration, expressed as percentage of the predicted normal value. Lower values indicate more significant airflow limitation.

Rescue inhaler usage per day

Average daily use of short-acting beta-agonist (SABA) rescue inhaler. Frequent rescue use signals poor asthma control and higher exacerbation risk.

GINA treatment step 4 or higher

Indicates medium-high dose inhaled corticosteroid / long-acting beta-agonist (ICS/LABA) therapy. Higher treatment steps suggest more difficult-to-control asthma.

Disclaimer: The RSE is an educational clinical decision-support tool developed in a specific population (poorly controlled asthma on GINA steps 3-4 with prior exacerbations). It does not replace comprehensive clinical assessment or individual risk-benefit discussions. Prospective validation in broader populations is still required. Always integrate with the full clinical picture, patient preferences, comorbidities, and current guidelines when making treatment decisions.

RSE Score: formula, variables, and clinical context

Overview

The Risk Score for Asthma Exacerbation (RSE) is a validated clinical tool developed by Bateman and colleagues to predict the risk of severe asthma exacerbations within 12 months of commencing treatment. It was derived from a retrospective analysis of 7,446 patients from three large randomised controlled trials comparing budesonide/formoterol maintenance and reliever therapy (MART) with fixed-dose ICS/LABA. The score was developed in two-thirds of the dataset and validated in the remaining one-third, with censoring at 6 months to include all three studies.

Scoring variables

Variable	Criteria	Points
BMI	≥ 30 kg/m²	+1
BMI	< 30 kg/m²	0
ACQ-5 score	< 1.5	0
	1.5 – 2.5	+1
	≥ 2.5	+2
Post-BD FEV1 (% predicted)	≥ 90%	0
	80% – 90%	+1
	< 80%	+2
Rescue inhaler use/day	< 2 puffs	0
	2 – 4 puffs	+1
	≥ 4 puffs	+2
GINA step 4 or higher	Yes (step 4+)	+1
GINA step 4 or higher	No (step 1–3)	0
Total score range		0-8

Risk interpretation

Score	Risk category	Clinical implication
0-2	Lower risk	Continue current therapy; reinforce adherence and trigger avoidance
3-4	Moderate risk	Optimise therapy; consider step-up or MART; address modifiable risk factors
5-6	High risk	Strongly consider step-up; specialist referral; written action plan
7-8	Very high risk	Specialist referral; biologic assessment; address comorbidities; close follow-up

The original study demonstrated an exponential increase in severe exacerbation risk with each additional RSE point. The RSE was developed as a continuous predictor; the categories above are provided for clinical context.

Variable definitions

BMI ≥ 30 kg/m² (1 point)

Body mass index calculated as weight (kg) divided by height squared (m²). A BMI ≥ 30 defines obesity per WHO criteria. Obesity is independently associated with worse asthma control and more frequent exacerbations through mechanisms including altered respiratory mechanics, increased airway inflammation, relative corticosteroid resistance, and comorbid conditions such as GERD and obstructive sleep apnoea.

ACQ-5 score (0, 1, or 2 points)

The 5-item Asthma Control Questionnaire (ACQ-5) assesses symptom control over the preceding week. Each of the five items (night-time waking, morning symptoms, activity limitation, shortness of breath, wheezing) is scored 0-6; the ACQ-5 is the mean score. A score < 1.5 indicates well-controlled asthma, 1.5-2.5 represents the "grey zone" of partial control, and ≥ 2.5 is considered uncontrolled (Juniper et al., 2006). Higher ACQ scores reflect greater symptom burden and are strongly predictive of future exacerbations (P < .001 in the RSE derivation cohort).

Post-bronchodilator FEV1 % predicted (0, 1, or 2 points)

Forced expiratory volume in one second (FEV1) measured after administration of a short-acting bronchodilator, expressed as a percentage of the age-, sex-, height-, and ethnicity-predicted normal value. A post-bronchodilator FEV1 < 80% predicted indicates persistent airflow limitation and is a GINA-recognised risk factor for exacerbations. Values between 80-90% represent mild reduction, while ≥ 90% is considered normal.

Rescue inhaler usage per day (0, 1, or 2 points)

Average daily use of short-acting beta-agonist (SABA) rescue inhaler (e.g., salbutamol/albuterol). GINA guidelines identify SABA overuse (particularly ≥ 3 canisters/year) as a risk factor for exacerbations and even asthma-related death. In the RSE, daily use < 2 puffs receives 0 points, 2-4 puffs receives 1 point, and ≥ 4 puffs receives 2 points, reflecting the dose-response relationship between reliever dependence and exacerbation risk.

GINA treatment step 4 or higher (1 point)

The Global Initiative for Asthma (GINA) treatment step reflects the current level of controller therapy. Step 4 corresponds to medium-high dose ICS/LABA combination therapy, while step 5 adds biologic agents or oral corticosteroids. Being on step 4+ therapy indicates more difficult-to-control asthma requiring higher treatment intensity, which is independently associated with greater exacerbation risk despite escalated treatment.

Study details

Design: Retrospective analysis of pooled data from three randomised, double-blind, parallel-group studies comparing budesonide/formoterol MART with fixed-dose ICS/LABA (budesonide/formoterol or salmeterol/fluticasone).
Population: 7,446 patients (mean age 39.5 years; 59% female) with asthma not controlled on GINA treatment steps 3-4 and with ≥ 1 exacerbation in the previous year.
Development: The RSE was developed in two-thirds of the dataset using multivariate logistic regression and validated in the remaining one-third. Censoring was applied at 6 months to include data from all three contributing studies.
Key finding: An exponential increase in the risk of severe exacerbation was observed with increments in the RSE score based on the five selected predictors.
Predictors evaluated: GINA step, reliever use, post-bronchodilator FEV1, and ACQ-5 were dominant predictors for both uncontrolled asthma and severe exacerbations (all P < .001). BMI was an additional dominant predictor specifically for severe exacerbations. Smoking status and asthma symptom scores were additional predictors for uncontrolled asthma (not included in the RSE).

Limitations

Retrospective derivation: The RSE was derived from clinical trial data with strict inclusion/exclusion criteria. Patients were required to have uncontrolled symptoms on GINA steps 3-4 with prior exacerbations, which may limit generalisability to milder asthma populations or treatment-naïve patients.
Prospective validation pending: While internally validated, the authors note that prospective validation in independent cohorts is required before routine clinical adoption.
Population characteristics: The study population was drawn from clinical trials in predominantly Western countries. The applicability to diverse ethnic populations, different healthcare settings, and patients with comorbidities typically excluded from RCTs has not been established.
ACQ-5 requirement: The ACQ-5 is not universally administered in clinical practice. Clinicians may need to implement this questionnaire specifically to use the RSE, which could limit point-of-care applicability.
Does not include all risk factors: Known risk factors such as smoking status, eosinophil count, blood eosinophils, allergen sensitisation, and exacerbation frequency are not included in the RSE, though they may influence individual risk.

Key references

Bateman ED, Buhl R, O'Byrne PM, et al. Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations. J Allergy Clin Immunol. 2015;135(6):1457-1464.e4.
Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the Asthma Control Questionnaire. Respir Med. 2005;99(5):553-558.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2024 update). Available at: ginasthma.org.
Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Eur Respir J. 2022;59(1):2102730.
Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 2006;100(7):1139-1151.

Practice caveats

The RSE was developed in patients with poorly controlled asthma on GINA steps 3-4 who had experienced at least one exacerbation in the prior year. Interpret with caution in patients outside this profile.
The RSE does not incorporate biomarkers (e.g., blood eosinophils, FeNO) that are increasingly used to guide biologic therapy. It should be considered alongside phenotypic assessment when making treatment decisions.
Rescue inhaler usage is self-reported and may be subject to recall bias. Objective measures of SABA use (e.g., electronic monitoring) may differ from patient-reported estimates.
The RSE was developed using data censored at 6 months. Risk estimates may not directly translate to longer follow-up periods, though the 12-month prediction framework was part of the study design.
Always integrate the RSE with the full clinical picture, including exacerbation history, comorbidities, inhaler technique, adherence, and environmental exposures when making management decisions.

Introduction

Asthma affects more than 300 million people worldwide and accounts for approximately 250,000 deaths annually. Despite the availability of effective controller therapies, a substantial proportion of patients experience severe exacerbations: episodes of progressive increase in symptoms (shortness of breath, cough, wheezing, chest tightness) that require urgent change in treatment, typically a course of systemic corticosteroids, an emergency department visit, or hospitalization. Severe exacerbations are the primary driver of asthma morbidity, mortality, healthcare costs, and impaired quality of life.

Predicting which patients are at greatest risk of future exacerbation is central to modern asthma management. While the single strongest predictor of a future exacerbation is a history of a prior exacerbation, clinicians have lacked a simple, validated, composite tool that integrates multiple risk factors into a single actionable score. The Risk Score for Asthma Exacerbation (RSE), developed by Bateman and colleagues and published in 2015, was designed to fill this gap.

The RSE was derived from a retrospective analysis of 7,446 patients with poorly controlled asthma (Global Initiative for Asthma [GINA] treatment steps 3-4) enrolled across three randomized controlled trials of budesonide/formoterol therapy. Using multivariable Cox proportional hazards modeling, the investigators identified five independent predictors of severe exacerbation within 12 months: body mass index (BMI), Asthma Control Questionnaire-5 (ACQ-5) score, post-bronchodilator FEV₁ (% predicted), daily rescue inhaler usage, and GINA treatment step. These five variables were combined into a simple 0-8 point scoring system that stratifies patients into four risk tiers, from lower risk to very high risk.

Historical Background and Development

Prior to the RSE, exacerbation risk assessment in asthma relied on individual clinical variables evaluated in isolation. Guidelines recommended identifying patients with risk factors for future exacerbations (poor control, low FEV₁, high SABA use, prior exacerbations, obesity, smoking, eosinophilia) but did not provide a method for combining these factors into a quantitative risk estimate. Clinicians were left to integrate these variables subjectively, leading to inconsistent risk stratification and suboptimal treatment decisions.

Bateman and colleagues recognized that a composite score would offer several advantages: standardization of risk assessment, identification of high-risk patients who might benefit from treatment escalation, and a quantitative metric for tracking risk over time. They leveraged individual patient data from three large Phase III clinical trials (studies assessing budesonide/formoterol in patients at GINA steps 3-4) that collectively enrolled 7,446 patients and tracked severe exacerbations over 6-12 months.

The derivation process involved testing a broad array of candidate predictors using multivariable Cox regression. Variables that independently predicted time to first severe exacerbation were retained, and their hazard ratios were translated into integer point values for simplicity. The resulting 5-variable, 8-point score was internally validated using bootstrap resampling and demonstrated good discrimination (C-statistic approximately 0.67) and calibration across the risk spectrum.

The RSE was specifically designed for patients with poorly controlled asthma on at least GINA step 3 therapy, the population in which exacerbation prediction is most clinically relevant. It was not intended for patients with mild, well-controlled asthma (who have low baseline exacerbation risk) or for patients in the acute setting (who are already experiencing an exacerbation).

The Five RSE Components

The RSE consists of five clinical variables. Two are binary (0 or 1 point each) and three are three-level (0, 1, or 2 points each), for a total score range of 0-8 points.

Variable	Category	Points
BMI	< 30 kg/m²	0
BMI	≥ 30 kg/m² (obese)	1
ACQ-5 Score	< 1.5 (well controlled)	0
	1.5 - 2.5 (partly controlled)	1
	≥ 2.5 (uncontrolled)	2
Post-BD FEV₁ (% predicted)	≥ 90% (normal)	0
	80-90% (mildly reduced)	1
	< 80% (reduced)	2
Rescue inhaler use (puffs/day)	< 2 puffs/day	0
	2-4 puffs/day	1
	≥ 4 puffs/day	2
GINA treatment step	Step 1-3	0
GINA treatment step	Step 4 or higher	1

Component 1: Body Mass Index (BMI ≥ 30 kg/m²)

Obesity, defined as a BMI of 30 kg/m² or greater, is an independent risk factor for asthma exacerbation. The relationship between obesity and asthma is complex, bidirectional, and involves multiple pathophysiological mechanisms:

Mechanical Effects

Excess adipose tissue in the chest wall and abdomen reduces functional residual capacity (FRC) and expiratory reserve volume (ERV), leading to breathing at lower lung volumes. At these reduced volumes, the airways are narrower, closing volumes are approached during tidal breathing, and peripheral airway resistance increases. This mechanical burden promotes air trapping, ventilation-perfusion mismatch, and dyspnea, all of which mimic and amplify asthma symptoms.

Systemic Inflammation

Adipose tissue is a metabolically active organ that secretes pro-inflammatory cytokines (adipokines) including leptin, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and resistin. These mediators promote systemic inflammation that may amplify airway inflammation in asthma. Obese patients with asthma often exhibit a non-eosinophilic (neutrophilic or paucigranulocytic) inflammatory phenotype that may be less responsive to inhaled corticosteroids.

Comorbid Conditions

Obesity is associated with gastroesophageal reflux disease (GERD), obstructive sleep apnea (OSA), and metabolic syndrome, all of which can worsen asthma control and increase exacerbation risk. GERD causes micro-aspiration and vagal-mediated bronchospasm; OSA contributes to nocturnal desaturation, systemic inflammation, and upper airway instability; and insulin resistance may directly impair airway smooth muscle function.

Therapeutic Implications

Obese patients with asthma tend to have a reduced response to inhaled corticosteroids and may require higher doses or alternative controller strategies. Weight loss of 5-10% of body weight has been shown to improve asthma control, reduce exacerbation frequency, and improve lung function parameters. Weight management should be explicitly addressed as part of the asthma management plan in patients with an RSE score elevated by the BMI criterion.

Component 2: Asthma Control Questionnaire-5 (ACQ-5) Score

The ACQ-5 is a validated, patient-reported outcome measure that quantifies asthma symptom control over the preceding week. It consists of five questions addressing:

Frequency of nighttime awakenings due to asthma
Severity of morning symptoms upon waking
Limitation of daily activities due to asthma
Degree of shortness of breath due to asthma
Frequency of wheezing

Each question is scored from 0 (no impairment) to 6 (maximum impairment), and the final ACQ-5 score is the mean of the five responses, ranging from 0 to 6. The RSE uses three categories:

ACQ-5 < 1.5 (well controlled): 0 points. This threshold has been validated as indicating well-controlled asthma with minimal symptom burden.
ACQ-5 1.5-2.5 (partly controlled): 1 point. Patients in this range have suboptimal control but are not severely impaired.
ACQ-5 ≥ 2.5 (uncontrolled): 2 points. A score of 2.5 or higher indicates uncontrolled asthma with significant daily symptom burden and the highest exacerbation risk from this component.

The ACQ-5 is the most heavily weighted symptom variable in the RSE because current symptom control is the strongest patient-reported predictor of near-term exacerbation risk. The minimally important difference (MID) for the ACQ is 0.5 points, meaning that a change of 0.5 or more represents a clinically meaningful change in control. Tracking ACQ-5 over time can therefore inform whether interventions are meaningfully reducing the patient's RSE score.

Component 3: Post-Bronchodilator FEV₁ (% Predicted)

Forced expiratory volume in one second (FEV₁) is the most widely used spirometric measure of airflow limitation. In the RSE, the post-bronchodilator FEV₁ is used, meaning the value measured after administration of a short-acting bronchodilator (typically salbutamol 400 μg). This reflects the patient's best achievable airflow and removes the confounding effect of variable bronchospasm.

The RSE uses FEV₁ expressed as a percentage of the predicted normal value (adjusted for age, sex, height, and ethnicity):

FEV₁ ≥ 90% predicted (normal): 0 points. Normal airflow suggests preserved airway caliber and lower exacerbation risk.
FEV₁ 80-90% predicted (mildly reduced): 1 point. Mild airflow limitation is present, indicating some degree of fixed or persistent airway narrowing.
FEV₁ < 80% predicted (reduced): 2 points. Significant airflow limitation is present, indicating structural airway changes (remodeling), mucus plugging, or persistent inflammation that limits airflow even after bronchodilator use.

Clinical Significance of Post-BD FEV₁

Post-bronchodilator FEV₁ is a powerful predictor of exacerbation risk because it reflects the cumulative burden of airway remodeling. Over time, chronic inflammation in asthma leads to subepithelial fibrosis, smooth muscle hypertrophy, mucus gland hyperplasia, and basement membrane thickening. These structural changes reduce airway caliber in a manner that is not fully reversible with bronchodilators. Patients with low post-BD FEV₁ have less "reserve" to tolerate further airway narrowing during an exacerbation and are more likely to develop severe symptoms requiring urgent intervention.

Studies have consistently demonstrated that every 10% decrease in post-BD FEV₁ below predicted normal is associated with an approximately 30-40% increase in the risk of severe exacerbation. The RSE captures this relationship through its three-tier scoring.

Component 4: Rescue Inhaler Usage (Puffs per Day)

Daily use of a short-acting beta-agonist (SABA) rescue inhaler, typically salbutamol (albuterol), is a direct marker of day-to-day symptom burden and a surrogate for inadequate controller therapy. The RSE categorizes daily rescue inhaler use as follows:

< 2 puffs/day: 0 points. Occasional rescue use is consistent with reasonable asthma control.
2-4 puffs/day: 1 point. Regular daily rescue use indicates breakthrough symptoms despite controller therapy.
≥ 4 puffs/day: 2 points. High rescue use reflects severely uncontrolled asthma with frequent or near-continuous symptoms.

SABA Over-Reliance and Risk

Excessive SABA use is both a marker and a driver of exacerbation risk. As a marker, it signals that the patient's underlying inflammation is inadequately suppressed by their controller regimen. As a driver, regular SABA use without adequate anti-inflammatory therapy promotes tachyphylaxis (reduced bronchodilator response), increased airway hyperresponsiveness, and paradoxical bronchospasm over time. The GINA 2019 update specifically identified SABA over-reliance as a major modifiable risk factor and recommended against the use of SABA-only treatment (without concurrent ICS) even in mild asthma.

Patients who report using ≥3 canisters of SABA per year (approximately ≥1.5 puffs/day averaged over the year) have been shown to have an increased risk of emergency department visits, hospitalizations, and death. This threshold roughly corresponds to the 2 puffs/day RSE criterion.

Maintenance-and-reliever therapy (MART), in which a combination ICS/formoterol inhaler is used as both the daily controller and the as-needed reliever, has been shown to reduce exacerbation rates compared to SABA-based relief strategies. The MART approach directly addresses the risk captured by this RSE component by ensuring that every "rescue" dose also delivers anti-inflammatory medication.

Component 5: GINA Treatment Step 4 or Higher

The GINA stepwise treatment approach classifies asthma management into five steps of escalating therapy:

GINA Step	Controller Therapy
Step 1	As-needed low-dose ICS-formoterol (or as-needed SABA + low-dose ICS)
Step 2	Low-dose ICS daily (or as-needed low-dose ICS-formoterol)
Step 3	Low-dose ICS/LABA
Step 4	Medium-dose ICS/LABA (± add-on therapies)
Step 5	High-dose ICS/LABA + phenotype-guided add-on (biologics, low-dose OCS, tiotropium)

The RSE assigns 1 point for patients at GINA step 4 or higher. Being on step 4+ therapy indicates that the patient requires medium-to-high dose ICS/LABA to maintain control, reflecting more severe underlying disease. These patients have already escalated beyond first-line combination therapy and are at the threshold where add-on therapies (tiotropium, leukotriene modifiers, biologics) are considered.

The inclusion of GINA step as an RSE variable captures an important concept: the treatment intensity required to achieve control is itself a risk marker. Two patients with identical ACQ-5 scores and FEV₁ values may have very different exacerbation risks if one achieves that level of control on low-dose ICS alone (step 2) while the other requires medium-dose ICS/LABA plus tiotropium (step 4). The latter patient has more severe underlying disease and a higher propensity for exacerbation.

Score Interpretation and Risk Stratification

The total RSE score (0-8) is stratified into four risk categories:

RSE Score	Risk Category	Clinical Interpretation
0-2	Lower Risk	Lower end of the risk spectrum. Continue current controller therapy with regular follow-up. Reinforce inhaler technique, adherence, and trigger avoidance. Consider step-down if well controlled for ≥ 3 months.
3-4	Moderate Risk	Meaningfully elevated exacerbation risk. Optimize controller therapy, verify inhaler technique, reassess adherence, and address modifiable risk factors. Consider step-up or switch to MART regimen.
5-6	High Risk	Proactive management warranted. Strongly consider step-up therapy, specialist referral, or biologic assessment. Provide a written asthma action plan and ensure access to oral corticosteroids for self-management.
7-8	Very High Risk	Highest risk category with exponentially greater exacerbation likelihood. Specialist referral strongly recommended. Evaluate phenotype-guided biologic therapy, address comorbidities, and ensure frequent follow-up.

The risk increase across categories is not linear but exponential: the hazard ratio for severe exacerbation increases progressively with each point, with patients scoring 7-8 having many times the risk of those scoring 0-2. This exponential relationship underscores the compounding effect of multiple concurrent risk factors.

Epidemiology of Asthma Exacerbations

Understanding the epidemiological burden of asthma exacerbations provides context for the clinical importance of the RSE:

Global prevalence: Asthma affects approximately 339 million people worldwide. In high-income countries, prevalence ranges from 5-15% of the adult population.
Exacerbation rates: Among patients with moderate-to-severe asthma, approximately 30-50% experience at least one exacerbation per year. Among those with poorly controlled asthma, the rate rises to 50-70%.
Healthcare utilization: Severe exacerbations account for the majority of asthma-related healthcare costs. In the United States alone, asthma-related emergency department visits number approximately 1.8 million per year, and hospitalizations exceed 180,000 per year.
Mortality: Globally, approximately 1,000 people die from asthma daily. The vast majority of asthma deaths occur during severe exacerbations and are largely preventable with appropriate controller therapy and exacerbation management.
Economic burden: The direct and indirect costs of asthma in the United States exceed $80 billion annually, with exacerbation-related costs (ED visits, hospitalizations, oral corticosteroid courses, missed work/school) accounting for the largest share.

Pathophysiology of Asthma Exacerbations

Asthma exacerbations result from a complex interplay of triggers, inflammatory cascades, and structural airway changes that produce acute airflow limitation:

Triggers

Common triggers for exacerbations include:

Respiratory viral infections: The most common trigger in both children and adults, responsible for approximately 80% of exacerbations in children and 50-60% in adults. Rhinovirus (the "common cold" virus) is the predominant pathogen. Viral infection of the airway epithelium impairs innate antiviral defense mechanisms (interferons), amplifies eosinophilic and neutrophilic inflammation, and increases airway hyperresponsiveness.
Allergen exposure: Sensitized individuals who are exposed to high concentrations of relevant allergens (house dust mites, pet dander, cockroach allergen, mold, pollen) may develop acute exacerbations through IgE-mediated mast cell degranulation and eosinophilic airway inflammation.
Air pollution: Particulate matter (PM2.5, PM10), ozone, nitrogen dioxide, and sulfur dioxide have all been associated with increased exacerbation rates, particularly in urban populations.
Medication non-adherence: Abrupt discontinuation or irregular use of ICS is one of the most important modifiable triggers for exacerbation. Without anti-inflammatory suppression, airway inflammation rebounds, increasing susceptibility to other triggers.
Exercise, cold air, and irritants: These triggers cause bronchospasm through airway cooling, water loss, or direct irritation of the airway epithelium.

Inflammatory Cascade

During an exacerbation, the airway inflammatory response escalates dramatically. Eosinophils, neutrophils, mast cells, and T-helper type 2 (Th2) lymphocytes infiltrate the airway mucosa, releasing mediators (histamine, leukotrienes, prostaglandins, cytokines) that cause bronchospasm, mucosal edema, and mucus hypersecretion. The combined effect of these processes narrows the airway lumen, increases airflow resistance, and produces the characteristic symptoms of wheezing, dyspnea, cough, and chest tightness.

Airway Remodeling

In patients with long-standing poorly controlled asthma, structural airway changes (remodeling) reduce the airway's ability to accommodate the additional inflammatory burden of an exacerbation. A patient with extensive subepithelial fibrosis and smooth muscle hypertrophy starts from a narrower baseline airway caliber, so even modest additional inflammation can produce critical airflow limitation. This is reflected in the RSE by the FEV₁ component: patients with low post-BD FEV₁ have more remodeling and less capacity to tolerate exacerbations without severe symptoms.

Risk Factors for Exacerbation Beyond the RSE

While the RSE captures five validated predictors, clinicians should be aware of additional risk factors not included in the score:

Prior exacerbation history: The single strongest predictor of future exacerbation. Patients who have experienced ≥1 severe exacerbation in the past 12 months are at 2-3 times the risk of future exacerbation compared to those who have not. The RSE derivation cohort included only patients with prior exacerbations (entry criterion for the clinical trials), so the score was not designed to discriminate based on exacerbation history within this population.
Blood eosinophil count: Peripheral blood eosinophilia (≥ 300 cells/μL) is associated with increased exacerbation risk and is also a predictor of response to biologic therapies targeting the Th2/eosinophilic pathway (mepolizumab, benralizumab, dupilumab).
Fractional exhaled nitric oxide (FeNO): Elevated FeNO (≥ 50 ppb in adults) reflects ongoing eosinophilic airway inflammation and predicts exacerbation risk, particularly in patients who are non-adherent with ICS.
Smoking status: Active smoking impairs corticosteroid sensitivity, accelerates lung function decline, and increases exacerbation frequency. Although not a direct RSE component, smoking status should be assessed and cessation strongly encouraged.
Psychosocial factors: Anxiety, depression, low health literacy, poor socioeconomic status, and lack of social support are all associated with poor asthma control and increased exacerbation risk.
Allergic sensitization: Sensitization to perennial allergens (dust mites, mold, pet dander) with ongoing exposure is a potent exacerbation trigger.
Comorbidities: Chronic rhinosinusitis with nasal polyps, GERD, obstructive sleep apnea, vocal cord dysfunction, and hormonal factors (perimenstrual asthma) all contribute to poor control and exacerbation risk.

Clinical Application: Step-by-Step

Assess BMI: Calculate from measured height and weight. Determine whether BMI ≥ 30 kg/m² (1 point) or < 30 (0 points).
Administer the ACQ-5: Have the patient complete the five-question ACQ-5 during the clinic visit. Calculate the mean score and assign 0, 1, or 2 points based on the thresholds (< 1.5, 1.5-2.5, ≥ 2.5).
Measure post-bronchodilator FEV₁: Perform spirometry after administering 400 μg salbutamol (or equivalent). Express FEV₁ as a percentage of predicted and assign 0, 1, or 2 points (≥ 90%, 80-90%, < 80%).
Assess rescue inhaler use: Ask the patient to estimate their average daily rescue inhaler use over the past week or two weeks. Assign 0, 1, or 2 points (< 2, 2-4, ≥ 4 puffs/day).
Determine GINA treatment step: Review the patient's current controller regimen and classify by GINA step. Assign 1 point if step 4 or higher, 0 if step 1-3.
Sum the total score: Add all points (range 0-8).
Interpret the risk category: Use the four-tier stratification to guide management intensity.
Act on the result: Implement risk-appropriate interventions (see Management Guided by RSE below).

Management Guided by RSE Risk Category

Lower Risk (RSE 0-2)

Maintain current controller therapy with regular review every 3-6 months.
Reinforce proper inhaler technique at each visit (studies show 70-80% of patients use their inhaler incorrectly).
Confirm medication adherence. Electronic monitoring and pharmacy refill data can provide objective adherence information.
Review and update the patient's written asthma action plan.
If the patient has been well controlled for ≥ 3 consecutive months, consider step-down therapy to identify the minimum effective controller dose.

Moderate Risk (RSE 3-4)

All lower-risk interventions plus a systematic search for modifiable risk factors.
Assess and address: incorrect inhaler technique, non-adherence, ongoing allergen or occupational exposure, active smoking, untreated rhinosinusitis, GERD, and obesity.
Consider step-up therapy: increase ICS dose, add a LABA if not already prescribed, or switch to a MART (maintenance-and-reliever therapy) regimen with ICS/formoterol.
Check blood eosinophils and FeNO to characterize the inflammatory phenotype, which may guide therapy selection.
Schedule follow-up in 4-8 weeks to reassess control and RSE score.

High Risk (RSE 5-6)

All moderate-risk interventions with increased urgency.
Strongly consider step-up to GINA step 4 or 5 therapy if not already at that level.
Referral to a respiratory/asthma specialist for phenotyping and consideration of add-on therapies (tiotropium, biologic agents).
Provide a comprehensive written asthma action plan with clear instructions for self-management of exacerbations, including when to start oral prednisolone and when to seek emergency care.
Ensure the patient has an emergency supply of oral corticosteroids at home.
Address comorbidities aggressively: weight management, GERD treatment, OSA screening, mental health assessment.
Schedule follow-up within 2-4 weeks.

Very High Risk (RSE 7-8)

All high-risk interventions with the addition of phenotype-guided biologic therapy assessment.
Specialist referral is strongly recommended if not already under specialist care.
Characterize the patient's asthma phenotype: eosinophilic (blood eos ≥ 150-300 cells/μL, elevated FeNO), allergic (elevated total IgE, sensitization to aeroallergens), or non-eosinophilic (neutrophilic or paucigranulocytic).
Biologic therapy options for eligible patients include:
- Anti-IgE (omalizumab): For allergic asthma with elevated IgE and demonstrated sensitization.
- Anti-IL-5/IL-5R (mepolizumab, benralizumab, reslizumab): For eosinophilic asthma with blood eosinophils ≥ 150-300 cells/μL.
- Anti-IL-4Rα (dupilumab): For eosinophilic asthma or corticosteroid-dependent asthma.
- Anti-TSLP (tezepelumab): Broad-spectrum biologic effective across inflammatory phenotypes.
Implement a multidisciplinary management plan including respiratory nursing, pharmacy, physiotherapy, psychology, and dietetics as appropriate.
Frequent follow-up (every 2-4 weeks) until the RSE score improves and the patient is stabilized.

Tracking RSE Over Time

A key advantage of the RSE is that three of its five components (ACQ-5, rescue inhaler use, and FEV₁) are dynamic and responsive to therapy. This allows the RSE to be recalculated at each clinic visit to track risk trajectory:

A declining RSE score over serial visits indicates that interventions are reducing exacerbation risk.
A stable or rising RSE score despite treatment changes signals the need for further escalation, specialist referral, or reassessment of adherence and modifiable factors.
BMI may change with weight management interventions, contributing to score reduction over months to years.
GINA treatment step may change with step-up or step-down therapy, though this paradoxically means that successful step-up (increasing from step 3 to step 4) would add 1 point to the RSE even though it may improve asthma control.

The RSE in Context: Comparison with Other Exacerbation Prediction Tools

GINA Risk Assessment

The GINA strategy document recommends a qualitative assessment of exacerbation risk factors (poor control, low FEV₁, high SABA use, prior exacerbations, eosinophilia, smoking, obesity) but does not provide a quantitative scoring system. The RSE operationalizes several of these GINA-identified risk factors into a numeric score, providing a more standardized and reproducible assessment.

Asthma APGAR

The Asthma APGAR (Activity limitation, Persistence of symptoms, triGGers, Asthma medications, Response to therapy) is a primary care tool for structured asthma assessment but does not generate a numeric exacerbation prediction score.

Composite Exacerbation Risk Indices

Several other composite indices have been proposed, including models incorporating blood eosinophils, FeNO, sputum eosinophils, and exacerbation history. These may offer incremental predictive value but are more complex and require laboratory or physiological measurements not routinely available in all clinical settings. The RSE's strength lies in its simplicity and reliance on variables obtainable during a standard clinic visit.

Strengths of the RSE

Derived from a large, well-characterized cohort: The score was developed from 7,446 patients across three randomized controlled trials, providing robust statistical power.
Uses readily available clinical variables: All five components (BMI, ACQ-5, FEV₁, rescue use, GINA step) are routinely assessed during standard asthma clinic visits. No specialized biomarkers or imaging studies are required.
Simple point-based system: The 0-8 scale with integer points is easy to calculate at the bedside without electronic tools or complex formulas.
Actionable risk stratification: The four-tier risk categorization maps directly to management recommendations, from maintenance and monitoring to specialist referral and biologic assessment.
Dynamic and trackable: Three of five components change with therapy, allowing serial RSE calculation to monitor risk trajectory over time.
Focuses on a clinically relevant population: The score targets patients at GINA steps 3-4 (the population in which exacerbation prediction is most impactful for management decisions).

Limitations of the RSE

Derived from clinical trial populations: The derivation cohort consisted of patients enrolled in budesonide/formoterol clinical trials, who met specific inclusion/exclusion criteria. Trial participants tend to have better adherence, closer monitoring, and more controlled comorbidities than real-world patients. The score's performance may differ in routine clinical practice.
Does not include exacerbation history: The strongest single predictor of future exacerbation is a prior exacerbation. This variable was not available as a discriminating factor in the RSE derivation because all patients in the clinical trials had a history of exacerbation (entry criterion). In clinical practice, exacerbation history should be assessed alongside the RSE.
Does not include blood eosinophils or FeNO: These type 2 inflammatory biomarkers are established predictors of exacerbation risk and biologic therapy response. Their omission limits the RSE's ability to characterize inflammatory phenotype or guide biologic selection.
ACQ-5 requirement: The ACQ-5 is a validated questionnaire but may not be routinely administered in all clinical settings. The Asthma Control Test (ACT), which is more widely used in primary care, is not interchangeable with the ACQ-5 and cannot be directly substituted into the RSE.
GINA step paradox: Step-up therapy (e.g., moving from step 3 to step 4) adds 1 point to the RSE, potentially increasing the score even if the step-up improves control and reduces exacerbation risk. Clinicians should interpret the GINA step component as a marker of disease severity rather than a modifiable target.
Moderate discrimination: The C-statistic of approximately 0.67 indicates moderate discriminatory ability. The RSE is better at population-level risk stratification than at making precise individual-level predictions.
Not validated in pediatric populations: The derivation studies enrolled adults. The RSE should not be applied to children without further validation.
Does not account for smoking, allergic sensitization, or comorbidities: These important risk factors are not captured by the score and must be assessed separately.

Clinical Pearls

The RSE is designed for patients with poorly controlled asthma on at least GINA step 3 therapy. It is not intended for patients with mild, well-controlled asthma or for acute exacerbation management.
Always assess prior exacerbation history alongside the RSE. A patient with an RSE of 2 but two hospitalizations in the past year carries higher risk than the score alone would suggest.
The ACQ-5 must be administered and scored correctly. A common error is substituting the ACQ-7 (which includes FEV₁ and SABA use items) or the ACT score. Only the 5-question symptom version (ACQ-5) is validated for the RSE.
Post-bronchodilator FEV₁ is specified, not pre-bronchodilator. Pre-BD values will overestimate airflow limitation and inflate the RSE score inappropriately.
Rescue inhaler use should be assessed as an average over the past 1-2 weeks, not based on a single day. Patients often underestimate their use; canister weight, dose counters, or electronic inhaler monitors can provide more objective data.
An RSE score of 7-8 identifies patients who should be strongly considered for biologic therapy. Before initiating biologics, confirm the inflammatory phenotype (blood eosinophils, FeNO, total IgE, allergen-specific IgE) to select the most appropriate agent.
Weight loss of 5-10% in obese asthmatic patients has been shown to improve ACQ scores, FEV₁, and exacerbation rates. In an obese patient with an RSE of 5 (including 1 point for BMI), a targeted weight management program could potentially reduce the RSE by 1-2 points through combined improvements in BMI and secondary improvement in ACQ-5 and FEV₁.
Recalculate the RSE at every structured asthma review (ideally every 1-3 months in moderate-to-severe asthma). Tracking the score over time provides a tangible metric for treatment response that can be communicated to patients and across healthcare providers.
The RSE does not replace comprehensive asthma assessment. It is a risk stratification tool that complements, rather than substitutes for, thorough history-taking, physical examination, spirometry, inflammatory biomarker assessment, and adherence evaluation.